Pyridoxine Dosing with Anti-Tuberculosis Treatment

Standard Prophylactic Dosing

The recommended dose of pyridoxine with isoniazid-containing anti-tuberculosis treatment is 25-50 mg daily for prophylaxis in at-risk patients, and 100 mg daily for treatment of established peripheral neuropathy, as recommended by the Clinical Infectious Diseases guidelines 1, 2
For patients at risk of neuropathy, administer pyridoxine 25-50 mg daily throughout the entire course of isoniazid therapy, according to the Clinical Infectious Diseases guidelines 1, 2, 3, 4

Pyridoxine supplementation is mandatory for pregnant women and breastfeeding infants receiving isoniazid, as recommended by the Clinical Infectious Diseases guidelines 1
Pyridoxine supplementation is also mandatory for HIV-infected persons receiving isoniazid, as recommended by the Clinical Infectious Diseases guidelines 5
Pyridoxine supplementation is mandatory for patients with alcoholism receiving isoniazid, as recommended by the Clinical Infectious Diseases guidelines 5
Pyridoxine supplementation is mandatory for malnourished patients receiving isoniazid, as recommended by the Clinical Infectious Diseases guidelines 1
Pyridoxine supplementation is mandatory for patients with chronic renal failure receiving isoniazid, as recommended by the Clinical Infectious Diseases guidelines 5

If peripheral neuropathy develops despite prophylaxis or in patients not receiving prophylaxis, increase pyridoxine to 100 mg daily, as recommended by the Clinical Infectious Diseases guidelines 1, 2, 3, 4

Do not exceed 100 mg/day for routine supplementation, as the European Food Safety Authority sets the upper tolerable intake level at 100 mg/day for adults, and higher doses can paradoxically cause sensory neuropathy, as recommended by the Praxis Medical Insights guidelines 6
Continue pyridoxine throughout the entire duration of isoniazid therapy, not just during the intensive phase, as recommended by the Clinical Infectious Diseases guidelines 1, 2

Pyridoxine (vitamin B6) prevents isoniazid‑induced peripheral neuropathy and should be given at 25–50 mg daily to all high‑risk patients receiving isoniazid for latent TB, including pregnant women, breastfeeding infants, HIV‑infected persons, and individuals with diabetes, alcoholism, malnutrition, chronic renal failure, or advanced age. 7
Pregnant women must receive pyridoxine 25–50 mg daily throughout the entire isoniazid course. 7
Breastfeeding infants require pyridoxine supplementation even when exposure is only through breast milk. 7
HIV‑infected persons are at particularly high risk for neuropathy and need prophylactic pyridoxine. 7
Patients with diabetes mellitus should receive routine pyridoxine supplementation during isoniazid therapy. 7
Individuals with alcoholism, malnutrition, chronic renal failure, or who are elderly should also receive routine supplementation. 7

Prophylactic dosing: Administer 25–50 mg pyridoxine daily to all at‑risk patients for the full duration of isoniazid treatment, not only during the intensive phase. 7
Therapeutic dosing: If peripheral neuropathy develops despite prophylaxis, increase the pyridoxine dose to 100 mg daily. 7

The recommendation for routine pyridoxine supplementation in latent TB treatment is derived from the highest‑quality guideline evidence (2016 American Thoracic Society / Centers for Disease Control and Prevention / Infectious Diseases Society of America Clinical Practice Guidelines). 7
Historical research demonstrated that low‑dose pyridoxine (≈6 mg daily) prevented neuropathy during high‑dose isoniazid therapy; modern guidelines have raised the prophylactic dose to 25–50 mg to ensure adequate protection across diverse populations. 7